RÉSUMÉ
Recientes publicaciones han puesto en duda la eficacia de la utilización de dosis terapéuticas o intermedias de heparina de bajo peso molecular (HBPM) en pacientes COVID-19, especialmente en los pacientes más graves. Con el objetivo de actualizar estas recomendaciones se ha realizado una revisión no sistemática en las principales bases de datos médicas. Se seleccionaron un total de 14 ensayos clínicos aleatorizados, 14 metaanálisis y las recomendaciones de 12 sociedades científicas, estratificadas según el tipo de paciente (ambulatorio, hospitalizado, ingresado en cuidados críticos o post-alta). Se ha analizado la eficacia de HBPM y también de otras aproximaciones terapéuticas (rivaroxabán, apixabán, sulodexida, ácido acetilsalicílico e inhibidores P2Y12). Los hallazgos recomiendan utilizar dosis estándar de HBPM como tromboprofilaxis en los pacientes COVID-19 hospitalizados críticos y dosis terapéutica en hospitalizados no críticos si el riesgo de sangrado es bajo. En los pacientes ambulatorios y dados de alta del hospital podría utilizarse HBPM a dosis profiláctica si existen factores de riesgo trombótico y el riesgo hemorrágico es bajo. No se recomienda asociar antiagregantes plaquetarios a la HBPM salvo indicación previa.(AU)
Recent publications have questioned the efficacy of using therapeutic or intermediate doses of low molecular weight heparin (LMWH) in COVID-19 patients, especially in the most severe patients. In order to update these recommendations, a non-systematic review has been carried out in the main medical databases. A total of 14 randomized clinical trials, 14 meta-analyses and the recommendations of 12 scientific societies were selected, stratified according to the type of patient (outpatient, hospitalized, admitted to critical care or post-discharge). The efficacy of LMWH and other therapeutic approaches (rivaroxaban, apixaban, sulodexide, acetylsalicylic acid and P2Y12 inhibitors) has been analyzed. The findings recommend using standard doses of LMWH as thromboprophylaxis in critically hospitalized COVID-19 patients and therapeutic doses in non-critically hospitalized patients with low bleeding risk. In outpatients and those discharged from the hospital, LMWH could be used at a prophylactic dose if there are thrombotic risk factors, and the bleeding risk is low. It is not recommended to associate antiplatelet agents with LMWH unless previously indicated.(AU)
Sujet(s)
Humains , Mâle , Femelle , /traitement médicamenteux , /épidémiologie , Héparine bas poids moléculaireRÉSUMÉ
Recent publications have questioned the efficacy of using therapeutic or intermediate doses of low molecular weight heparin (LMWH) in COVID-19 patients, especially in the most severe patients. In order to update these recommendations, a non-systematic review has been carried out in the main medical databases. A total of 14 randomized clinical trials, 14 meta-analyses and the recommendations of 12 scientific societies were selected, stratified according to the type of patient (outpatient, hospitalized, admitted to critical care or post-discharge). The efficacy of LMWH and other therapeutic approaches (rivaroxaban, apixaban, sulodexide, acetylsalicylic acid and P2Y12 inhibitors) has been analyzed. The findings recommend using standard doses of LMWH as thromboprophylaxis in critically hospitalized COVID-19 patients and therapeutic doses in non-critically hospitalized patients if the risk of bleeding is low. In outpatients and those discharged from the hospital, LMWH could be used at a prophylactic dose if there are thrombotic risk factors, and the bleeding risk is low. It is not recommended to associate antiplatelet agents with LMWH unless previously indicated.
Sujet(s)
COVID-19 , Thromboembolisme veineux , Humains , Héparine bas poids moléculaire/usage thérapeutique , Anticoagulants/usage thérapeutique , COVID-19/complications , Post-cure , Thromboembolisme veineux/étiologie , Thromboembolisme veineux/prévention et contrôle , Thromboembolisme veineux/traitement médicamenteux , Sortie du patientRÉSUMÉ
La infección por el coronavirus SARS-CoV-2, causante de la enfermedad denominada COVID-19, provoca alteraciones fundamentalmente en el sistema respiratorio. En los pacientes graves, con frecuencia la enfermedad evoluciona a un síndrome de distrés respiratorio agudo que puede predisponer a los pacientes a un estado de hipercoagulabilidad, con trombosis tanto a nivel venoso como arterial. Esta predisposición presenta una fisiopatología multifactorial, relacionada tanto con la hipoxia como con el grave proceso inflamatorio ligado a esta patología, además de los factores trombóticos adicionales presentes en muchos de los pacientes.Ante la necesidad de optimizar el manejo de la hipercoagulabilidad, los grupos de trabajo de las sociedades científicas de Anestesiología-Reanimación y Terapéutica del Dolor (SEDAR) y de Medicina Intensiva, Crítica y de Unidades Coronarias (SEMICYUC) han desarrollado un consenso para establecer unas pautas de actuación frente a las alteraciones de la hemostasia observadas en los pacientes graves COVID-19. Estas recomendaciones incluyen la profilaxis de la enfermedad tromboembólica venosa en pacientes graves y en el periparto, el manejo de los pacientes en tratamiento crónico con fármacos antiagregantes o anticoagulantes, de las complicaciones hemorrágicas en la evolución de la enfermedad y de la interpretación de las alteraciones generales de la hemostasia
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis
Sujet(s)
Humains , Infections à coronavirus/thérapie , Syndrome respiratoire aigu sévère/thérapie , Troubles de l'hémostase/thérapie , Virus du SRAS/pathogénicité , Anticoagulants/administration et posologie , Fibrinolytiques/administration et posologie , Antiagrégants plaquettaires/administration et posologie , Infections à coronavirus/physiopathologie , Thrombophilie/thérapie , Maladie catastrophique/thérapie , Pandémies , Héparine bas poids moléculaire/administration et posologie , Complications infectieuses de la grossesse/thérapieRÉSUMÉ
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.
Sujet(s)
Anticoagulants/usage thérapeutique , Betacoronavirus , Troubles de l'hémostase et de la coagulation/prévention et contrôle , Infections à coronavirus/complications , Antiagrégants plaquettaires/usage thérapeutique , Pneumopathie virale/complications , Anticoagulants/administration et posologie , Troubles de l'hémostase et de la coagulation/étiologie , COVID-19 , Infections à coronavirus/sang , Infections à coronavirus/épidémiologie , Femelle , Hémorragie/thérapie , Humains , Pandémies , Antiagrégants plaquettaires/administration et posologie , Pneumopathie virale/sang , Pneumopathie virale/épidémiologie , Grossesse , Complications hématologiques de la grossesse/sang , Complications hématologiques de la grossesse/étiologie , Complications hématologiques de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/sang , Complications infectieuses de la grossesse/étiologie , Complications infectieuses de la grossesse/prévention et contrôle , SARS-CoV-2 , Thromboembolie/étiologie , Thromboembolie/prévention et contrôle , Thrombose/étiologieRÉSUMÉ
BACKGROUND: Some studies have been performed to assess the effects of levosimendan on cardiac function when administered to cardiac surgery patients with low cardiac output syndrome (LCOS) in the immediate postoperative period. Levosimendan is an inotropic agent for the treatment of low cardiac output syndrome that seems to have a protective effect on renal function. METHODS: It is a quasi-experimental study. A total of 100 patients with LCOS received either beta-agonists or levosimendan. We assessed the incidence of postoperative kidney failure in cardiac surgery patients. In patients who had kidney failure at diagnosis of LCOS, we examined whether differences existed in the evolution of kidney failure based on the treatment administered for LCOS. The parameters measured included haemodynamics, oxygen supply, and renal function as assessed by the AKI scale. ANOVA, Student's t-test and Wilcoxon or Friedman tests were used. RESULTS: Up to 30% of cardiac surgery patients had kidney failure at diagnosis of LCOS. Kidney failure at discharge from the ICU was more frequent in patients who received beta-agonist drugs as compared to those who received levosimendan (p < 0.05). CONCLUSION: The incidence of kidney failure decreased with the postoperative administration of levosimendan to cardiac surgery patients with LCOS, as compared to beta-agonists. TRIAL REGISTRATION: Current Controlled Trials ISRCTN 46058317. Date of registration: 7/10/2019. Retrospectively registered.
Sujet(s)
Agonistes bêta-adrénergiques/administration et posologie , Bas débit cardiaque/traitement médicamenteux , Procédures de chirurgie cardiaque/méthodes , Cardiotoniques/administration et posologie , Simendan/administration et posologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Bas débit cardiaque/physiopathologie , Femelle , Humains , Incidence , Mâle , Adulte d'âge moyen , Complications postopératoires/épidémiologie , Complications postopératoires/prévention et contrôle , Insuffisance rénale/épidémiologie , Insuffisance rénale/prévention et contrôleRÉSUMÉ
No disponible
Sujet(s)
Humains , Anticoagulants/administration et posologie , Dabigatran/administration et posologie , Procédures de chirurgie opératoire/méthodes , Surveillance des médicaments/méthodes , Algorithmes , Traitement d'urgence/méthodes , Interactions médicamenteuses , Abstention thérapeutique , Fibrinolytiques/administration et posologie , Insuffisance rénale/épidémiologie , Insuffisance hépatique/épidémiologie , Anticorps monoclonaux humanisés/pharmacocinétiqueRÉSUMÉ
No disponible
Sujet(s)
Humains , Antiagrégants plaquettaires/administration et posologie , Perte sanguine peropératoire/prévention et contrôle , Période périopératoire , Traitement par apport liquidien/méthodes , Inhibiteurs des cyclooxygénases/administration et posologie , Antagonistes des récepteurs purinergiques P2Y/administration et posologie , Inhibiteurs de la phosphodiestérase/administration et posologie , Complexe glycoprotéique IIb-IIIa de la membrane plaquettaire/antagonistes et inhibiteurs , Hémostase , Anesthésie de conduction/méthodesSujet(s)
Algorithmes , Anticorps monoclonaux humanisés/usage thérapeutique , Antithrombiniques/usage thérapeutique , Dabigatran/antagonistes et inhibiteurs , Dabigatran/usage thérapeutique , Traitement d'urgence , Procédures de chirurgie opératoire , Anticorps monoclonaux humanisés/pharmacologie , Inhibiteurs du facteur Xa/usage thérapeutique , HumainsSujet(s)
Soins périopératoires/normes , Antiagrégants plaquettaires/usage thérapeutique , Algorithmes , Arbres de décision , Hémorragie/induit chimiquement , Hémorragie/prévention et contrôle , Humains , Antiagrégants plaquettaires/effets indésirables , Appréciation des risques , Procédures de chirurgie opératoireRÉSUMÉ
INTRODUCTION: Epilepsy is a chronic disease with high prevalence. Its impact in the quality of life is influenced by factors like disease characteristics, comorbidities, stigma perception and treatment adherence. AIM: To assess the quality of life, the social stigma and the treatment adherence of patients with epilepsy in our area. PATIENTS AND METHODS: Descriptive, observational and cross-sectional study. Sociodemographic and clinical data were collected. We analyzed data on quality of life (QUOLIE-10), social stigma and treatment adherence through different questionnaires. RESULTS: 40 patients were studied. The mean age was 42.43 ± 17.20 years, and the onset of epilepsy was 25.88 ± 16.81 years. 55% were women. The score in the quality of life questionnaire was 19.28 ± 8.03 points in men and 17.00 ± 7.69 for women, this difference being not significant. There were also no significant differences for social stigma, with a mean of 11.50 ± 13.47 points in men and 6.00 ± 10.36 points for women (p = 0.152). According to the treatment adherence questionnaire (Morisky-Green), 70% of the patients studied were compliant with the treatment. CONCLUSIONS: Patients with epilepsy in our environment have a good quality of life, probably related to good treatment adherence and compliance. There is low perceived social stigma but people with epilepsy still trend to hide their condition.
TITLE: Valoracion de la calidad de vida, estigma social y adhesion al tratamiento en pacientes con epilepsia del Area de Salud de Caceres: estudio transversal.Introduccion. La epilepsia es una enfermedad cronica, con elevada prevalencia. La repercusion de la epilepsia en la calidad de vida de las personas que la padecen se ve influida por factores como las caracteristicas de la enfermedad, la presencia de comorbilidad, la percepcion de estigma social y la adhesion al tratamiento. Objetivo. Valorar la calidad de vida, el estigma social y la adhesion al tratamiento de pacientes con epilepsia de nuestra area. Pacientes y metodos. Estudio descriptivo, observacional y transversal. Se recogieron datos sociodemograficos y clinicos. Analizamos datos sobre la calidad de vida (Quality of Life in Epilepsy-10), el estigma social y la adhesion al tratamiento a traves de diferentes cuestionarios. Resultados. Se estudio a 40 pacientes, con una media de edad de 42,43 ± 17,2 años y una media de edad de inicio de la epilepsia de 25,88 ± 16,81 años. El 55% fueron mujeres. La puntuacion en el cuestionario sobre calidad de vida fue de 19,28 ± 8,03 puntos para los hombres y 17,00 ± 7,69 para las mujeres, y esta diferencia no fue significativa. Tampoco se observaron diferencias significativas para el estigma social: media de 11,50 ± 13,47 puntos para los hombres y 6,00 ± 10,36 para las mujeres (p = 0,152). Segun el cuestionario de adhesion terapeutica (Morisky-Green), el 70% de los pacientes fue cumplidor del tratamiento. Conclusiones. Los pacientes con epilepsia tienen una buena calidad de vida, que creemos atribuible a la buena adhesion y el cumplimiento del tratamiento. Se detecta una baja percepcion de estigma social, pero los pacientes tienden a ocultar el diagnostico.
Sujet(s)
Épilepsie/traitement médicamenteux , Adhésion au traitement médicamenteux/statistiques et données numériques , Qualité de vie , Stigmate social , Adulte , , Études transversales , Femelle , Humains , Mâle , Autorapport , EspagneRÉSUMÉ
No disponible
Sujet(s)
Humains , Antiagrégants plaquettaires/usage thérapeutique , Anticoagulants/usage thérapeutique , Facteurs de risque , Utilisation médicament/normes , Antibioprophylaxie/normes , Évaluation préopératoire/méthodes , Dabigatran/usage thérapeutique , Rivaroxaban/usage thérapeutiqueRÉSUMÉ
Estos últimos años han aparecido alertas de seguridad, no siempre bien sustentadas, que cuestionan el uso de algunas alternativas farmacológicas a la transfusión de sangre alogénica y/o lo restringen en indicaciones establecidas. Asistimos también a la preconización de otras alternativas, incluyendo productos hemáticos y fármacos antifibrinolíticos, sin que haya una base científica sólida que lo justifique. Por iniciativa del Grupo de Estudios Multidisciplinares sobre Autotransfusión y del Anemia Working Group España se reunió a un panel multidisciplinar de 23 expertos del área de cuidados de la salud en un foro de debate para: 1) analizar las diferentes alertas de seguridad en torno a ciertas alternativas a la transfusión; 2) estudiar los antecedentes que las han propiciado, la evidencia que las sustentan y las consecuencias que conllevan para la práctica clínica, y 3) emitir una valoración argumentada de la seguridad de cada alternativa a la transfusión cuestionada, según el uso clínico de la misma. Los integrantes del foro mantuvieron contactos por vía telemática y una reunión presencial en la que presentaron y discutieron las conclusiones sobre cada uno de los elementos examinados. Se elaboró un primer documento que fue sometido a 4 rondas de revisión y actualización hasta alcanzar un consenso, unánime en la mayoría de los casos. Presentamos la versión final del documento, aprobada por todos los miembros del panel, esperando sea de utilidad para nuestros colegas
In recent years, several safety alerts have questioned or restricted the use of some pharmacological alternatives to allogeneic blood transfusion in established indications. In contrast, there seems to be a promotion of other alternatives, based on blood products and/or antifibrinolytic drugs, which lack a solid scientific basis. The Multidisciplinary Autotransfusion Study Group and the Anemia Working Group España convened a multidisciplinary panel of 23 experts belonging to different healthcare areas in a forum for debate to: 1) analyze the different safety alerts referred to certain transfusion alternatives; 2) study the background leading to such alternatives, the evidence supporting them, and their consequences for everyday clinical practice, and 3) issue a weighted statement on the safety of each questioned transfusion alternative, according to its clinical use. The members of the forum maintained telematics contact for the exchange of information and the distribution of tasks, and a joint meeting was held where the conclusions on each of the items examined were presented and discussed. A first version of the document was drafted, and subjected to 4 rounds of review and updating until consensus was reached (unanimously in most cases). We present the final version of the document, approved by all panel members, and hope it will be useful for our colleagues
Sujet(s)
Humains , Transfusion sanguine autologue/méthodes , Transfusion sanguine/méthodes , Hémorragie postopératoire/thérapie , Soins de réanimation/méthodes , Unités de soins intensifs/organisation et administration , Érythropoïèse/physiologie , Facteur VIII/pharmacocinétique , Colloïdes/pharmacocinétique , Sécurité des patientsRÉSUMÉ
Existe un amplio consenso sobre el manejo perioperatorio de los pacientes tratados con los nuevos anticoagulantes orales directos (dabigatrán, ribaroxabán y apixabán) en cirugía programada. Por el contrario, en la actualidad no existe este nivel de acuerdo en cirugía urgente, especialmente en el paciente sangrante. Por este motivo, se ha realizado una revisión bibliográfica a través del buscador PubMed en la base de datos MEDLINE de los artículos publicados entre 2000-2014 referidos a los términos «monitorización» y «reversión» de los fármacos mencionados. Guías de práctica clínica, revisiones sistemáticas, revisiones y artículos sobre la materia se incluyeron en la búsqueda. Se verifica un limitado papel de los test rutinarios de coagulación (tiempo de protrombina y tiempo parcial de tromboplastina activado) en el manejo perioperatorio de estos pacientes. Así mismo, muestran la ausencia de antídotos específicos, aunque plantean la posibilidad de usar concentrado de complejo protrombínico y factor vii activado recombinante en la reversión urgente de su efecto anticoagulante (AU)
There is an almost unanimous consensus on the management of the direct new oral anticoagulants, dabigatran, rivaroxaban, and apixaban in elective surgery. However, this general consensus does not exist in relation with the direct new oral anticoagulants use in emergency surgery, especially in the bleeding patient. For this reason, a literature review was performed using the MEDLINE-PubMed. An analysis was made of the journal articles, reviews, systematic reviews, and practices guidelines published between 2000 and 2014 using the terms monitoring and reversal. From this review, it was shown that the routine tests of blood coagulation, such as the prothrombin time and activated partial thromboplastin time, have a limited efficacy in the perioperative control of blood coagulation in these patients. There is currently no antidote to reverse the effects of these drugs, although the possibility of using concentrated prothrombin complex and recombinant activated factor vii has been suggested for the urgent reversal of the anticoagulant effect (AU)
Sujet(s)
Femelle , Humains , Mâle , Période périopératoire/méthodes , Période périopératoire/normes , Période périopératoire , Anticoagulants/usage thérapeutique , 34628 , Thromboplastine/usage thérapeutique , Soins périopératoires/méthodes , Soins périopératoires/instrumentation , Soins périopératoires , Tests de coagulation sanguine/méthodesRÉSUMÉ
In recent years, several safety alerts have questioned or restricted the use of some pharmacological alternatives to allogeneic blood transfusion in established indications. In contrast, there seems to be a promotion of other alternatives, based on blood products and/or antifibrinolytic drugs, which lack a solid scientific basis. The Multidisciplinary Autotransfusion Study Group and the Anemia Working Group España convened a multidisciplinary panel of 23 experts belonging to different healthcare areas in a forum for debate to: 1) analyze the different safety alerts referred to certain transfusion alternatives; 2) study the background leading to such alternatives, the evidence supporting them, and their consequences for everyday clinical practice, and 3) issue a weighted statement on the safety of each questioned transfusion alternative, according to its clinical use. The members of the forum maintained telematics contact for the exchange of information and the distribution of tasks, and a joint meeting was held where the conclusions on each of the items examined were presented and discussed. A first version of the document was drafted, and subjected to 4 rounds of review and updating until consensus was reached (unanimously in most cases). We present the final version of the document, approved by all panel members, and hope it will be useful for our colleagues.
Sujet(s)
Anémie/thérapie , Maladie grave/thérapie , Hémorragie/thérapie , Anémie/traitement médicamenteux , Antifibrinolytiques/effets indésirables , Antifibrinolytiques/usage thérapeutique , Aprotinine/effets indésirables , Aprotinine/usage thérapeutique , Facteurs de la coagulation sanguine/effets indésirables , Facteurs de la coagulation sanguine/usage thérapeutique , Transfusion sanguine/normes , Essais cliniques comme sujet , Cristalloïdes , Érythropoïétine/effets indésirables , Érythropoïétine/usage thérapeutique , Antianémiques/effets indésirables , Antianémiques/usage thérapeutique , Humains , Hydroxyéthylamidons/effets indésirables , Hydroxyéthylamidons/usage thérapeutique , Fer/effets indésirables , Fer/usage thérapeutique , Solution isotonique/effets indésirables , Solution isotonique/usage thérapeutique , Méta-analyse comme sujet , Études observationnelles comme sujet , Substituts du plasma/effets indésirables , Substituts du plasma/usage thérapeutique , Protéines recombinantes/effets indésirables , Protéines recombinantes/usage thérapeutique , Acide tranéxamique/effets indésirables , Acide tranéxamique/usage thérapeutique , Réaction transfusionnelleRÉSUMÉ
There is an almost unanimous consensus on the management of the direct new oral anticoagulants, dabigatran, rivaroxaban, and apixaban in elective surgery. However, this general consensus does not exist in relation with the direct new oral anticoagulants use in emergency surgery, especially in the bleeding patient. For this reason, a literature review was performed using the MEDLINE-PubMed. An analysis was made of the journal articles, reviews, systematic reviews, and practices guidelines published between 2000 and 2014 using the terms "monitoring" and "reversal". From this review, it was shown that the routine tests of blood coagulation, such as the prothrombin time and activated partial thromboplastin time, have a limited efficacy in the perioperative control of blood coagulation in these patients. There is currently no antidote to reverse the effects of these drugs, although the possibility of using concentrated prothrombin complex and recombinant activated factor vii has been suggested for the urgent reversal of the anticoagulant effect.
Sujet(s)
Antithrombiniques/usage thérapeutique , Inhibiteurs du facteur Xa/usage thérapeutique , Hémorragie/prévention et contrôle , Soins périopératoires/méthodes , Administration par voie orale , Antithrombiniques/administration et posologie , Facteurs de la coagulation sanguine/usage thérapeutique , Tests de coagulation sanguine , Perte sanguine peropératoire , Surveillance des médicaments , Urgences , Facteur VIIa/usage thérapeutique , Inhibiteurs du facteur Xa/administration et posologie , Hémorragie/induit chimiquement , Hémorragie/traitement médicamenteux , Techniques d'hémostase , Humains , Hémorragie postopératoire/induit chimiquement , Hémorragie postopératoire/traitement médicamenteux , Hémorragie postopératoire/prévention et contrôle , Guides de bonnes pratiques cliniques comme sujet , Protéines recombinantes/usage thérapeutiqueRÉSUMÉ
New direct oral anticoagulant agents (DOAC) are currently licensed for thromboprophylaxis after hip and knee arthroplasty and for long-term prevention of thromboembolic events in non-valvular atrial fibrillation as well as treatment and secondary prophylaxis of venous thromboembolism. Some other medical indications are emerging. Thus, anaesthesiologists are increasingly likely to encounter patients on these drugs who need elective or emergency surgery. Due to the lack of experience and data, the management of DOAC in the perioperative period is controversial. In this article, we review available information and recommendations regarding the periprocedural management of the currently most clinically developed DOAC, apixaban, dabigatran, and rivaroxaban. We discuss two trends of managing patients on DOAC for elective surgery. The first is stopping the DOAC 1-5 days before surgery (depending on the drug, patient and bleeding risk) without bridging. The second is stopping the DOAC 5 days preoperatively and bridging with low-molecular-weight heparin. The management of patients on DOAC needing emergency surgery is also reviewed. As no data exist for the use of haemostatic products for the reversal of the anticoagulant effect in these cases, rescue treatment recommendations are proposed.
Sujet(s)
Anticoagulants/administration et posologie , Hémorragie/prévention et contrôle , Thromboembolie/prévention et contrôle , Administration par voie orale , Sujet âgé , Anesthésiologie , Anticoagulants/composition chimique , Arthroplastie prothétique de hanche , Arthroplastie prothétique de genou , Benzimidazoles/administration et posologie , Dabigatran , Femelle , Hémostase , Héparine bas poids moléculaire/usage thérapeutique , Humains , Mâle , Morpholines/usage thérapeutique , Sécurité des patients , Période périopératoire , Pyrazoles/usage thérapeutique , Pyridones/usage thérapeutique , Rivaroxaban , Thiophènes/usage thérapeutique , bêta-Alanine/administration et posologie , bêta-Alanine/analogues et dérivésRÉSUMÉ
La transfusión de sangre alogénica (TSA) no es inocua, y como consecuencia han surgido múltiples alternativas a la misma (ATSA). Existe variabilidad respecto a las indicaciones y buen uso de las ATSA. Dependiendo de la especialidad de los médicos que tratan a los pacientes, el grado de anemia, la política transfusional, la disponibilidad de las ATSA y el criterio personal, estas se usan de forma variable. Puesto que las ATSA tampoco son inocuas y pueden no cumplir criterios de coste-efectividad, la variabilidad en su uso es inaceptable. Las sociedades españolas de Anestesiología y Reanimación (SEDAR), Hematología y Hemoterapia(SEHH), Farmacia Hospitalaria (SEFH), Medicina Intensiva y Unidades Coronarias(SEMICYUC), Trombosis y Hemostasia (SETH) y Transfusiones Sanguíneas (SETS) han elaborado un documento de consenso para el buen uso de la ATSA. Un panel de expertos de las 6sociedades ha llevado a cabo una revisión sistemática de la literatura médica y elaborado el 2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Solo se contempla las ATSA dirigidas a disminuir la transfusión de concentrado de hematíes. Se definen las ATSA como toda medida farmacológica y no farmacológica encaminada a disminuir la transfusión de concentrado de hematíes, preservando siempre la seguridad del paciente. La cuestión principal que se plantea en cada ítem se formula, en forma positiva o negativa, como: La ATSA en cuestión reduce/no reduce la tasa transfusional». Para formular el grado de recomendación se ha usado la metodología Grades of Recommendation Assessment, Development and Evaluation (GRADE) (AU)
Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH)and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: Does this particular AABT reduce the transfusion rate or not? All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation(GRADE) methodology (AU)
Sujet(s)
Humains , Transfusion sanguine autologue , Transfusion sanguine/méthodes , Substituts sanguins/usage thérapeutique , Anémie/thérapie , Hémoglobine glyquée/usage thérapeutique , Fibrinogène/usage thérapeutique , Types de pratiques des médecinsRÉSUMÉ
La transfusión de sangre alogénica (TSA) no es inocua, y como consecuencia han surgido múltiples alternativas a la misma (ATSA). Existe variabilidad respecto a las indicaciones y buen uso de las ATSA. Dependiendo de la especialidad de los médicos que tratan a los pacientes, el grado de anemia, la política transfusional, la disponibilidad de las ATSA y el criterio personal, estas se usan de forma variable. Puesto que las ATSA tampoco son inocuas y pueden no cumplir criterios de coste-efectividad, la variabilidad en su uso es inaceptable. Las sociedades españolas de Anestesiología y Reanimación (SEDAR), Hematología y Hemoterapia (SEHH), Farmacia Hospitalaria (SEFH), Medicina Intensiva y Unidades Coronarias (SEMICYUC), Trombosis y Hemostasia (SETH) y Transfusiones Sanguíneas (SETS) han elaborado un documento de consenso para el buen uso de la ATSA. Un panel de expertos de las 6 sociedades ha llevado a cabo una revisión sistemática de la literatura médica y elaborado el 2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Solo se contempla las ATSA dirigidas a disminuir la transfusión de concentrado de hematíes. Se definen las ATSA como toda medida farmacológica y no farmacológica encaminada a disminuir la transfusión de concentrado de hematíes, preservando siempre la seguridad del paciente. La cuestión principal que se plantea en cada ítem se formula, en forma positiva o negativa, como: «La ATSA en cuestión reduce/no reduce la tasa transfusional». Para formular el grado de recomendación se ha usado la metodología Grades of Recommendation Assessment, Development and Evaluation (GRADE) (AU)
Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: "Does this particular AABT reduce the transfusion rate or not?" All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) methodology (AU)